COMMUNIQUÉS West-GlobeNewswire

BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Kα Breaker, at the San Antonio Breast Cancer Symposium (SABCS)
10/12/2025
Preclinical data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα, strongly inhibits pAKT signaling in tumor cells without inducing hyperglycemia, and shows robust anti-tumor activity both as monotherapy [...]
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
10/12/2025
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to enroll All patients [...]
GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
10/12/2025
Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used with existing [...]
DLH Reports Fiscal 2025 Fourth Quarter Results
10/12/2025
ATLANTA, Dec. 10, 2025 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of digital transformation and cybersecurity, systems engineering and integration, and science [...]
Intuitive Announces Expanded Indications for da Vinci SP
10/12/2025
FDA clearance expands da Vinci SP indications to include inguinal hernia repair, cholecystectomy, and appendectomy SUNNYVALE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology [...]
Clearmind Medicine Announces 1-for-40 Reverse Share Split
10/12/2025
Vancouver, Canada, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel [...]
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
10/12/2025
Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, including those who have relapsed or are refractory to checkpoint inhibitors, a multi-billion [...]
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
10/12/2025
– Company addresses FDA requests regarding formulation excipient – Global site start-up activities continue, with first-patient-in for registrational Phase 1b study targeted for Q1 2026, subject to FDA feedback [...]
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/12/2025
SAN DIEGO , Dec. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on December 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock [...]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
10/12/2025
NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Kaya Pai Panandiker, the new Chief Commercial Officer of [...]
Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11/12/2025
DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“ [...]
Tiny Health Celebrates 100,000 Tests Milestone, Expands from Baby Gut Health Pioneer to Longevity Innovator
10/12/2025
The microbiome startup powering preventive and personalized health launches new aging study and deepens partnerships with leading wellness and longevity programs AUSTIN, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Tiny [...]
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
10/12/2025
Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation Phase 2 results presented at 2025 San Antonio Breast Cancer Symposium BOSTON, Dec. 10, 2025 ( [...]
MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
10/12/2025
CHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted [...]
Priority Partners Opening Two More Free Mini-Pantries in Maryland
10/12/2025
New Cupboards Target Food Insecurity In Time for Holidays HANOVER, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Priority Partners’ Cupboards Project is celebrating the season of giving with the launch of two new free self- [...]
EmblemHealth Announces New Agreement with the Hospital for Special Surgery
10/12/2025
City workers will retain access to the country’s highest-ranked orthopedic center NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) -- With the New York City Employees (NYCE) PPO health plan going live January 1, EmblemHealth [...]
Une utilisation précoce de CARVYKTI®▼ (ciltacabtagène autoleucel) a permis d’obtenir des rémissions durables sans traitement pendant 2,5 ans chez des patients atteints d’un myélome multiple en rechute ou réfractaire
10/12/2025
Les données de suivi issues de l’étude CARTITUDE-4 révèlent qu’au moins 80 pour cent des patients à risque standard traités n’ont présenté aucune progression de la maladie et n’ont reçu aucun traitement après une [...]
Valneva annonce des résultats finaux de Phase 2 positifs sur la persistance des anticorps et l’innocuité de son vaccin contre le chikungunya IXCHIQ® chez les enfants
10/12/2025
IXCHIQ ® a été bien toléré par les enfants âgés d’un à onze ans indépendamment de la dose de vaccin reçue ou d’une précédente infection au virus du chikungunya Les niveaux d’anticorps demeurent élevés après douze mois [...]
Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ®
10/12/2025
IXCHIQ ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups, although more [...]

Pages